SPDR S&P Biotech ETF Rating $154.26 +2.26 (+1.49%) As of 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock SPDR S&P Biotech ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XBI Aggregate RatingModerate Buy 2.77Holdings in XBI have an aggregate rating of Moderate Buy based on 415 analyst ratings issued in the past year covering 25 companies (30.6% of the portfolio).XBI Aggregate Price Target$154.26High Prediction$154.26Average Prediction$154.26Low Prediction$154.26Holdings in XBI have an aggregate price target of $154.26 and a range of $154.26 to $154.26 covering 25 companies (30.6% of the portfolio).XBI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy20 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Biotech ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 XBI Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings1.49%APGEApogee Therapeutics$134.00-0.1%1.8651 of 5 stars2.24$121.25 -9.5%21Short Interest Decrease1.41%KYMRKymera Therapeutics$115.77+1.6%1.5288 of 5 stars2.86$122.64 5.9%22Analyst Forecast1.37%MRNAModerna$61.82-2.1%1.7648 of 5 stars1.82$38.27 -38.1%17Gap Down1.29%VKTXViking Therapeutics$37.08+2.0%2.9048 of 5 stars2.79$93.60 152.4%14News Coverage1.28%ERASErasca$19.17+0.8%1.3254 of 5 stars2.64$20.64 7.6%11Trending NewsAnalyst Forecast1.26%CGONCG Oncology$71.85+3.4%3.0778 of 5 stars2.71$81.73 13.7%14Insider TradeOptions Volume1.25%ORKAOruka Therapeutics$92.70+11.6%3.1626 of 5 stars2.82$134.30 44.9%11Analyst UpgradeHigh Trading Volume1.25%PRAXPraxis Precision Medicines$314.41+2.0%3.4962 of 5 stars2.95$563.50 79.2%22Gap Down1.23%TWSTTwist Bioscience$93.85+2.9%1.9179 of 5 stars2.70$90.30 -3.8%10Analyst Forecast1.20%SYRESpyre Therapeutics$100.23+6.5%1.471 of 5 stars2.92$101.42 1.2%131.20%RVMDRevolution Medicines$186.16+3.9%1.9386 of 5 stars2.95$144.00 -22.6%22Positive News1.20%MIRMMirum Pharmaceuticals$118.86+1.3%3.062 of 5 stars2.93$143.40 20.6%151.19%SRRKScholar Rock$52.86+2.2%2.0784 of 5 stars3.12$56.00 5.9%17Positive News1.18%PCVXVaxcyte$56.20+0.3%2.2597 of 5 stars2.44$86.00 53.0%9Analyst Downgrade1.18%BBIOBridgeBio Pharma$81.38+1.3%3.5346 of 5 stars2.83$95.21 17.0%23Analyst ForecastAnalyst Revision1.18%DNTHDianthus Therapeutics$105.60+10.7%1.8577 of 5 stars2.93$117.82 11.6%141.17%CYTKCytokinetics$80.18-0.2%3.0077 of 5 stars2.91$99.90 24.6%22Insider TradeOptions Volume1.17%RYTMRhythm Pharmaceuticals$106.60+0.5%2.7921 of 5 stars2.76$138.29 29.7%17News CoveragePositive NewsGap Up1.17%RLAYRelay Therapeutics$19.91+2.8%2.6471 of 5 stars3.00$24.17 21.4%13Analyst Forecast1.17%ROIVRoivant Sciences$34.51+1.7%1.8684 of 5 stars2.75$33.59 -2.7%121.16%INSMInsmed$108.32+0.8%4.1004 of 5 stars2.96$211.05 94.8%25News CoverageAnalyst ForecastGap Down1.15%PTGXProtagonist Therapeutics$140.91+6.7%1.5771 of 5 stars2.94$123.00 -12.7%17Positive NewsAnalyst Forecast1.15%RAREUltragenyx Pharmaceutical$29.28-3.1%3.6034 of 5 stars2.83$58.41 99.5%18Positive NewsGap Down1.15%NTRANatera$271.39+0.6%2.1859 of 5 stars2.82$267.83 -1.3%22News CoverageAnalyst Forecast1.14%COGTCogent Biosciences$39.08+3.0%1.596 of 5 stars2.86$43.73 11.9%14 This page (NYSEARCA:XBI) was last updated on 7/17/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XBI Stock Alerts